Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNtech) in Aotearoa New Zealand
Lancet | 3 Feb 2023 Abstract Background: In February 2021, New Zealand began its largest ever immunisation programme with the BNT162b2 mRNA COVID-19 vaccine. We aimed to understand the association between 12 adverse events of special interest (AESIs) and a primary dose of BNT162b2 in the New Zealand population, aged ≥ 5 years, from 19…